These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The predictive value of OCT characteristics for the visual outcome in neovascular AMD. Kolb S; Menghini M; Barthelmes D; Sutter F; Kurz-Levin M Klin Monbl Augenheilkd; 2012 Apr; 229(4):343-7. PubMed ID: 22496000 [TBL] [Abstract][Full Text] [Related]
29. [Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV)]. Maier M; Feucht N; Haas K; Fiore B; Winkler von Mohrenfels C; Clos A; Lohmann C Klin Monbl Augenheilkd; 2008 Sep; 225(9):818-24. PubMed ID: 18759214 [TBL] [Abstract][Full Text] [Related]
30. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Robin AL; Clark AF; Covert DW; Krueger S; Bergamini MV; Landry TA; Dickerson JE; Scheib SA; Realini T; Defaller JM; Cagle GD Am J Ophthalmol; 2009 Jan; 147(1):45-50.e2. PubMed ID: 18789793 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Cleary CA; Jungkim S; Ravikumar K; Kelliher C; Acheson RW; Hickey-Dwyer M Eye (Lond); 2008 Jan; 22(1):82-6. PubMed ID: 17891059 [TBL] [Abstract][Full Text] [Related]
32. [Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration]. Kloos P; Bernasconi P; Estermann S; Bachmann B; Rutishauser Y; Thölen A Klin Monbl Augenheilkd; 2008 May; 225(5):385-91. PubMed ID: 18454378 [TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320 [TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689 [TBL] [Abstract][Full Text] [Related]
36. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Geltzer A; Turalba A; Vedula SS Cochrane Database Syst Rev; 2007 Oct; (4):CD005022. PubMed ID: 17943833 [TBL] [Abstract][Full Text] [Related]
37. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related]
38. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]
39. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454 [TBL] [Abstract][Full Text] [Related]